Weekly Ophthalmic Newsletter

1. FDA Recalls Eye Ointments Sold at Walmart and CVS Over Infection Risk

Eye ointment products manufactured in India and sold in the United States at major retailers like Walmart and CVS Pharmacy are being recalled due to a danger of infection. Brassica Pharma Pvt. Ltd., based in Maharashtra, India, announced the recall of various eye lubricant products labeled Equate, CVS Health, and AACE. The recalled products have expiration dates ranging from February 2024 to September 2025.

Brassica Pharma noted that no reports of adverse events tied to the ointments have been received thus far. However, consumers, distributors, and retailers are urged to discontinue the distribution and use of the affected products.

Click here to read the full article.

2. PulseSight Therapeutics Introduces Novel Gene Therapies for Retinal Diseases

PulseSight Therapeutics has launched to advance two novel late-stage preclinical drugs for wet and dry age-related macular diseases (AMD), including geographic atrophy (GA).

At the heart of PulseSight's innovation lies their proprietary non-viral gene therapy ocular platform, leveraging an electro-transfection system. This system delivers DNA plasmids encoding therapeutic proteins into the ciliary muscle, presenting a promising approach to treating major eye diseases.

Click here to read the full article.

3. Researchers Develop Faster, Cheaper 3D Printing Technique for Artificial Eyeballs

A team of biomedical and ophthalmological researchers from various European institutions, in collaboration with computer graphics specialists, has unveiled a novel technique for 3D printing artificial eyeballs. Published in the esteemed journal Nature Communications, their innovative approach promises to revolutionize the process, offering a faster, more accurate, and cost-effective alternative to conventional methods.

In their pioneering work, the research team turned to 3D printing technology to streamline the process, significantly reducing both time and cost while improving the likelihood of a proper fit. The first step involved identifying a suitable material akin to polymethyl methacrylate for printing. Subsequently, optical coherence tomography was employed to scan the empty eye socket, with the obtained data fed into a computer modeling application.

Click here to read the full article.

4. CorNeat Vision Launches CorNeat EverPatch in the U.S.

CorNeat Vision has launched the CorNeat EverPatch in the United States, a novel synthetic tissue-integrating matrix poised to transform ophthalmic surgeries. Endorsed by leading surgeons across the US, this FDA-cleared device marks a significant advancement in addressing complications associated with surgical interventions on the ocular surface.

The CorNeat EverPatch serves as a synthetic tissue substitute for ocular surface surgeries, offering a distinctive blend of features that surpass existing tissue grafts prone to degradation over time. Its innovative structure facilitates seamless integration with surrounding tissue without eliciting a chronic foreign body response, while its non-degradable nature provides lasting reinforcement to the ocular surface.

Click here to read the full article.

5. N4 Pharma Advances Novel Delivery Systems Toward Commercialisation

N4 Pharma Plc , a pre-clinical stage specialist pharmaceutical company, has achieved progress toward the commercialisation of its innovative delivery systems, Nuvec® and LipTide®. This advancement follows the company's recent acquisition of a controlling interest in Nanogenics Limited, a developer of a unique lipid and peptide-based delivery system, LipTide®, which is being used in the formulation of a novel siRNA product, ECP105, in the ophthalmology market.

Click here to read the full article.

If you want to stay updated with the latest news via e-mail, click here to subscribe.